Assessing acute systemic effects of an inhaled drug with serial echocardiography: a placebo-controlled comparison of inhaled and intravenous dihydroergotamine

Robert J Noveck, Pamela S Douglas, Shein-Chung Chow, Barry Mangum, Shashidhar Kori, Donald J Kellerman, Robert J Noveck, Pamela S Douglas, Shein-Chung Chow, Barry Mangum, Shashidhar Kori, Donald J Kellerman

Abstract

Objective: MAP0004 is an investigational product which delivers dihydroergotamine (DHE) through the lung via a breath-synchronized metered dose inhaler. The objective of this study was to compare the acute effects of orally inhaled and intravenous (IV) DHE to placebo on maximum change and area under the curve for pulmonary arterial systolic pressure (PASP).

Research design and methods: A randomized, double-blind, placebo-controlled, 3-period, crossover study of 24 health adults. Trial registration NCT01089062. Study assessments included pharmacokinetics, electrocardiograms (ECG), and validated echocardiographic (Doppler)-derived measures of PASP by echocardiogram. The primary endpoint was the absolute change in calculated PASP using area under the curve, 0 to 2 hours (AUC(0-2h)).

Results: The change in PASP with IV DHE was significantly different than MAP0004 and placebo (AUC(0-2h)2857, 2624, and 2453 mmHg*min, respectively). After a second dose of MAP0004, AUC(0-4h) remained lower with MAP0004 than with a single dose of IV DHE. Adverse events were more common with IV DHE than with MAP0004 or placebo. None of the treatments produced clinically significant changes in PASP or other cardiac parameters. Changes in PASP were significantly smaller with MAP0004 compared with IV DHE.

Conclusion: These results indicate the effects 1 mg of orally inhaled DHE on the cardiovascular system are less than with 1 mg of IV DHE, and that serial echocardiography can be a useful noninvasive means of assessing acute systemic effects.

Keywords: MAP0004; dihydroergotamine; echo; echocardiogram; inhaled; intravenous; pulmonary artery systolic pressure.

Figures

Figure 1
Figure 1
Mean plasma DHE concentrations over time with IV DHE 1.0 mg and MAP0004 1.0 mg. Abbreviations: DHE, dihydroergotamine; IV, intravenous.

References

    1. Shrewsbury SB, Cook RO, Taylor G, Edwards C, Ramadan NM. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a Novel (Tempo) inhaler. Headache. 2008;48(3):355–367.
    1. Shrewsbury SB, Kori S, Miller SD, Pedinoff A, Weinstein S. Randomized, double blind, placebo controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics. Curr Med Res Opin. 2008;24(7):1977–1985.
    1. Forst A, Febbraro S, Kellerman D, et al. An open-label, two-period crossover study comparing the pharmacokinetics and tolerability of LEVADEX™ (MAP0004, orally inhaled DHE) and intravenous DHE (DHE45®) in smoking and non-smoking adult volunteers. Headache. 2011;51(Suppl 1):17. Abstract P31.
    1. Kellerman D, Kori S, Forst A, et al. Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humans. Cephalalgia. 2012 Jan;32(2):150–158.
    1. Aurora SK, Rozen TD, Kori S, Shrewsbury SB. A randomized, double blind, placebo controlled study of MAP0004 in adult patients with migraine. Headache. 2009;49(6):826–837.
    1. Aurora SK, Silberstein SD, Kori SH, et al. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache. 2011;51(4):507–517.
    1. Lang RM, Bierig M, Devereux RB, et al. Chamber Quantification Writing Group; American Society of Echocardiography’s Guidelines and Standards Committee; European Association of Echocardiography Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440–1463.
    1. Milan A, Magnino C, Veglio F. Echocardiographic indexes for the non-invasive evaluation of pulmonary hemodynamics. J Am Soc Echocardiogr. 2010;23(3):225–239.
    1. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010;23(7):685–713.
    1. Fisher MR, Criner GJ, Fishman AP, et al. NETT Research Group Estimating pulmonary artery pressures by echocardiography in patients with emphysema. Eur Respir J. 2007;30(5):914–921.
    1. Fisher MR, Forfia PR, Chamera E, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009;179(7):615–621.
    1. Naeije R, Torbicki A. More on the non-invasive diagnosis of pulmonary hypertension: Doppler echocardiography revisited. Eur Respir J. 1995;8(9):1445–1449.
    1. Tramarin R, Torbicki A, Marchandise B, Laaban JP, Morpurgo M. Doppler echocardiographic evaluation of pulmonary artery pressure in chronic obstructive pulmonary disease. A European multicentre study. Working Group on Noninvasive Evaluation of Pulmonary Artery Pressure. European Office of the World Health Organization, Copenhagen. Eur Heart J. 1991;12(2):103–111.
    1. Subhedar NV, Shaw NJ. Intraobserver variation in Doppler ultrasound assessment of pulmonary artery pressure. Arch Dis Child Fetal Neonatal Ed. 1996;75(1):F59–F61.
    1. Humbert H, Cabiac MD, Dubray C, Lavène D. Human pharmacokinetics of dihydroergotamine administered by nasal spray. Clin Pharmacol Ther. 1996;60(3):265–275.
    1. Cook RO, Shrewsbury SB, Ramadan NM. Reduced adverse event profile of orally inhaled DHE (MAP0004) vs IV DHE: potential mechanism. Headache. 2009;49(10):1423–1434.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel